Regulatory News: <\/p>\n
Cellectis plant sciences, the plant genome engineering company and subsidiary of Cellectis SA (Paris:ALCLS), has signed two new agreements with Bayer CropScience, a subsidiary of Bayer AG and a leader in the areas of seeds, crop protection and non-agricultural pest control, on gene editing in plants. The agreements extend the companies existing partnership to introduce targeted modifications to selected plant genes and genomes. The financial terms of these agreements are not disclosed. <\/p>\n
The first aim of this extended partnership is to collaboratively create commercial traits for the canola seed market using new technologies developed by Cellectis plant sciences. The second aim is to provide Bayer with access to technologies that enable the directed engineering of plant genomes, such as gene stacking and targeted mutagenesis, for the development of improved crops. <\/p>\n
These novel technologies work efficiently in plant cells and will be an important tool to improve crops, said Catherine Feuillet, Head of Trait Research at Bayer CropScience. They facilitate the creation of specific modifications in the plant genome or genes and thus minimize the genetic footprint left behind. <\/p>\n
These new agreements position Cellectis plant sciences as a key partner for Bayer CropScience, commented Luc Mathis, CEO of Cellectis plant sciences. Following the technical success we have achieved with all our programs in potatoes and oil crops, such as soybean and canola, the development of new commercial products relevant for the food industry has become the focus of our company. <\/p>\n
About Cellectis plant sciences Established in March 2010, Cellectis plant sciences is a subsidiary of Cellectis (Alternext: ALCLS) dedicated to the applications of nucleases in plants. Its main mission is to increase and accelerate usage of Cellectiss proprietary technology in agricultural biology, broaden the companys platform to attract new and expanded licensing opportunities and explore the development of proprietary traits for selected applications. Cellectis plant sciences is located in New Brighton, Minnesota, USA. Professor Daniel Voytas, Chief Scientific Officer of Cellectis plant sciences, is also Director of the University of Minnesota Center for Genome Engineering. For further information, please visit our website: http:\/\/www.cellectis.com<\/a> <\/p>\n About Cellectis Cellectis is a biopharmaceutical company focused on oncology. The companys mission is to develop a novel generation of therapy based on allogeneic T-cell to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering -based on TALEN, meganuclease, and, the state-of-the-art electroporation technology Pulsagile- to create the 4th generation of cancer immunotherapy to treat leukemia and solid tumors. Cellectis adoptive cancer immunotherapy to cure chronic and acute leukemias is based on the first allogeneic T-cell Chimeric Antigen Receptor (CAR) technology. CAR technologies are designed to target cell surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and use leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: http:\/\/www.cellectis.com<\/a>. <\/p>\n About Bayer CropScience Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 8,383 million (2012) and is one of the worlds leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 20,800 and is represented in more than 120 countries. This and further news is available at: http:\/\/www.press.bayercropscience.com<\/a> <\/p>\n Disclaimer This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Companys objectives based on the current expectations and assumptions of the Companys management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements. <\/p>\n<\/p>\n <\/p>\n Read more from the original source: Regulatory News: Cellectis plant sciences, the plant genome engineering company and subsidiary of Cellectis SA (Paris:ALCLS), has signed two new agreements with Bayer CropScience, a subsidiary of Bayer AG and a leader in the areas of seeds, crop protection and non-agricultural pest control, on gene editing in plants. The agreements extend the companies existing partnership to introduce targeted modifications to selected plant genes and genomes. Continue reading
\nCellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"